Patient outcomes
| End point . | ADE (n = 151) . | ADEP (n = 151) . | P . |
|---|---|---|---|
| CR, n (%) | 114 (75) | 113 (75) | .999 |
| DFS | .740 | ||
| Median, y | 1.34 | 1.09 | |
| Percentage of DFS at 5 y (95% CI) | 36 (28-45) | 36 (27-45) | |
| OS | .824 | ||
| Median, y | 1.86 | 1.69 | |
| Percentage alive at 5 y (95% CI) | 37 (30-45) | 37 (29-45) |
| End point . | ADE (n = 151) . | ADEP (n = 151) . | P . |
|---|---|---|---|
| CR, n (%) | 114 (75) | 113 (75) | .999 |
| DFS | .740 | ||
| Median, y | 1.34 | 1.09 | |
| Percentage of DFS at 5 y (95% CI) | 36 (28-45) | 36 (27-45) | |
| OS | .824 | ||
| Median, y | 1.86 | 1.69 | |
| Percentage alive at 5 y (95% CI) | 37 (30-45) | 37 (29-45) |
ADE indicates cytosine arabinoside, daunorubicin, and etoposide; ADEP, cytosine arabinoside, daunorubicin, etoposide, and PSC-833; CR, complete remission; DFS, disease-free survival; CI, confidence interval; OS, overall survival.